RxDoctor Payments Data

Kathryn Gillen, DO

Pulmonary Disease · Saint Paul, MNNPI 1356635007

Payments from drug & device makers

$342in general payments, 2019–2025

Across 23 payments — averaging $14.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$162
  • Boehringer Ingelheim$79
  • AbbVie$35
  • Amgen$23
  • AstraZeneca$17
  • La Jolla Pharmaceutical Company$14
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$342100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$342 in reported general payments places this provider in the 60th percentile of 261 pulmonary disease providers in Minnesota.

See all pulmonary disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$49,917
Medicare patients
176
Services billed
601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter120$93,897
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$19,849
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$15,217
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$12,338
Breo ElliptaFluticasone/Vilanterol24$9,266
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$5,800
SymbicortBudesonide/Formoterol Fumarate18$5,687
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$3,156
Albuterol Sulfate HfaAlbuterol Sulfate91$2,856
Fluticasone Propionate12$199
Prednisone30$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$162$115,501171 claims
AstraZenecaBreztri Aerosphere, Symbicort$17$25,53647 claims
Boehringer IngelheimStiolto Respimat$79$15,21717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 261 pulmonary disease providers in Minnesota.

Other pulmonary disease in Saint Paul

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →